Marchex

AI-Driven Platforms Will Expand Enterprise Market Reach

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

08 Apr 25

Updated

15 Aug 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-22.6%

-1.8%

-22.6%

-1.8%

You can edit this narrative until Aug 15 6:45 AM. Then, changes will post as Updates.

Author's Valuation

US$459.0% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates2

Shared on 15 Aug 25

Marchex’s modestly higher future P/E ratio and slight weakening in net profit margin suggest incrementally greater valuation risk, but the consensus price target remains unchanged at $4.00. What's in the News Marchex launched an AI-powered healthcare solution to provide health systems and marketing organizations with actionable insights from patient conversations, enhancing attribution, appointment prioritization, and marketing optimization.

Shared on 17 Apr 25

Fair value Increased 24%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

US$4

59.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

4.41%

Media revenue growth rate

0.17%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.96%

Calculation

US$5.24m

Earnings '28

42.78x

PE Ratio '28

US$224.00m

Market Cap '28

US$224.00m

Market Cap '28

46.23m

No. shares '28

US$4.84

Share Price '28

US$4.84 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$3.98

Fair Value '25